P/E at 35.45 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflecting Market Confidence?

The current P/E ratio of Sun Pharmaceutical Industries Ltd at 35.45 stands noticeably above the sector average of 31.90. This premium suggests that investors are willing to pay more for each rupee of earnings compared to the broader Pharmaceuticals & Biotechnology industry. Such a valuation gap often implies expectations of superior earnings growth or a perception of stronger fundamentals relative to peers. However, it also raises questions about whether the premium is justified given the company’s recent performance trends — Sun Pharmaceutical Industries Ltd has underperformed the sector in certain short-term periods, which merits closer scrutiny.

Performance Across Timeframes: A Mixed Momentum Story

Examining the stock’s returns reveals a divergence between short- and medium-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has gained 2.55%, outperforming the Sensex’s 6.20% decline. The one-month and three-month returns are also positive at 1.36% and 3.31% respectively, contrasting sharply with the Sensex’s losses of 9.51% and 14.25% over the same periods. Year-to-date, the stock is up 3.30% while the Sensex has fallen 14.80%. This relative strength in recent months suggests resilience amid broader market weakness. Yet, the stock’s day-to-day performance shows some volatility, with a 1.06% decline today and a recent two-day losing streak following consecutive gains — is this a temporary pause or a sign of shifting momentum? The data invites a deeper look into whether the recent gains can be sustained or if they represent a short-lived rally.

Moving Average Configuration: Bullish Across All Key Levels

The technical setup for Sun Pharmaceutical Industries Ltd is notably robust, with the stock trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment indicates a strong upward trend across both short- and long-term horizons, a configuration often interpreted as bullish. The stock is also just 3.87% below its 52-week high of Rs 1850.95, signalling proximity to recent peak levels. However, the recent two-day decline after consecutive gains suggests some profit-taking or consolidation — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The moving average picture provides a framework to assess whether the current momentum can be sustained or if a correction is imminent.

Sector Performance Context: Mixed Results Amidst Industry Volatility

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 34 stocks having declared results so far: 16 positive, 9 flat, and 9 negative. This distribution reflects a sector grappling with varied operational and market challenges. Against this backdrop, Sun Pharmaceutical Industries Ltd’s ability to maintain positive returns over multiple timeframes and trade above all major moving averages stands out. Yet, the sector’s uneven performance also highlights the importance of monitoring company-specific developments closely — how will the sector’s evolving dynamics influence the stock’s trajectory?

Rating Reassessment: Previously Hold, Now Updated

On 23 Feb 2026, Sun Pharmaceutical Industries Ltd’s rating was updated from a previous Hold status. The Mojo Score stands at 72.0, reflecting a solid overall assessment. This reassessment comes amid the stock’s premium valuation and mixed but generally positive performance metrics. The rating update invites investors to consider the implications of the company’s current standing — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Long-Term Performance: Outpacing the Sensex Over Several Years

Looking beyond the recent year, Sun Pharmaceutical Industries Ltd has delivered impressive returns over the medium and long term. The three-year return stands at 79.32%, significantly ahead of the Sensex’s 25.28%. Over five years, the stock has surged 197.31%, dwarfing the Sensex’s 44.83% gain. However, the ten-year return of 118.89% trails the Sensex’s 186.57%, indicating a period of relative underperformance in the more distant past. This long-term data underscores the company’s capacity for substantial growth in recent years, though it also highlights the cyclical nature of its performance within the broader market context.

Market Capitalisation and Sector Positioning

With a market capitalisation of approximately Rs 4,26,253.85 crore, Sun Pharmaceutical Industries Ltd firmly holds its place as a large-cap entity within the Pharmaceuticals & Biotechnology sector. This scale provides the company with significant resources and market influence, factors that often contribute to its premium valuation. The sector itself is characterised by innovation, regulatory challenges, and competitive pressures, all of which shape the performance and valuation of constituent stocks.

Conclusion: What the Data Collectively Shows

The data on Sun Pharmaceutical Industries Ltd paints a picture of a stock trading at a valuation premium relative to its industry, supported by solid medium- and long-term performance and a bullish technical setup. The stock’s outperformance against the Sensex over one year and shorter periods contrasts with some recent volatility and profit-taking, suggesting a nuanced momentum profile. The sector’s mixed results add complexity to the outlook, while the recent rating reassessment from Hold to a new status signals a shift in analytical perspective. Taken together, these factors invite investors to carefully weigh valuation against performance trends — what is the current rating for Sun Pharmaceutical Industries Ltd?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →